Abstract
Recently we demonstrated that prolonged administration of IFN-γ prevented the development of GVHD in a MHC-mismatched murine BMT model. Treatment with IFN-γallowed the development of mature donor-derived allo-tolerant immunocompetent cells in complete chimeric recipients. Here we present data on the pharmacodynamics of this cytokine-mediated protection against GVHD. Treatment with 50000 U IFN-γ twice weekly for a period of 5 weeks, starting at the day of BMT, was shown to be the optimal treatment protocol, resulting in complete prevention of GVHD-related mortality. Treatment during 1 week with a three-fold higher weekly dose of IFN-γ (50000 U six times) did not result in significantly improved survival. The start of IFN-γ administration was a critical factor since a delay of 3 days from the time of BMT resulted in substantial GVHD-induced mortality. Furthermore, it was shown that IFN-γ treatment inhibited the spontaneous and Con-A-induced proliferation of T cells at 7–14 days after BMT, which is the critical period for the initiation of acute GVHD. However, long-term survivors after IFN-γ treatment showed a recovery of immunity in contrast to long-term survivors of saline-injected animals, as tested by Con-A responsiveness. It seems that injection of high dose IFN-γ suppresses the response of potentially alloreactive donor T cells during what normally is the initiation phase of the GVH reaction (GVHR), resulting in the abrogation of GVHD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brok, H., Vossen, J. & Heidt, P. IFN-γ-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells. Bone Marrow Transplant 22, 1005–1010 (1998). https://doi.org/10.1038/sj.bmt.1701478
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701478
Keywords
This article is cited by
-
Advances in graft-versus-host disease biology and therapy
Nature Reviews Immunology (2012)
-
TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model
Nature Biotechnology (2003)
-
Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction
International Journal of Hematology (2001)